nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—Ethinyl Estradiol—osteoporosis	0.107	0.42	CbGbCtD
Neostigmine—ABCB1—Conjugated Estrogens—osteoporosis	0.0787	0.309	CbGbCtD
Neostigmine—ABCB1—Estradiol—osteoporosis	0.0691	0.271	CbGbCtD
Neostigmine—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00448	0.115	CbGpPWpGaD
Neostigmine—ACHE—Monoamine Transport—TNFRSF11B—osteoporosis	0.00174	0.0446	CbGpPWpGaD
Neostigmine—Pollakiuria—Estradiol—osteoporosis	0.00171	0.00242	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.0017	0.00241	CcSEcCtD
Neostigmine—Hypersensitivity—Etidronic acid—osteoporosis	0.00169	0.0024	CcSEcCtD
Neostigmine—Loss of consciousness—Risedronate—osteoporosis	0.00169	0.0024	CcSEcCtD
Neostigmine—Insomnia—Calcitriol—osteoporosis	0.00169	0.00239	CcSEcCtD
Neostigmine—Mental disorder—Zoledronate—osteoporosis	0.00168	0.00239	CcSEcCtD
Neostigmine—Agitation—Pamidronate—osteoporosis	0.00168	0.00238	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00167	0.00237	CcSEcCtD
Neostigmine—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00167	0.00236	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00166	0.00236	CcSEcCtD
Neostigmine—Somnolence—Calcitriol—osteoporosis	0.00166	0.00235	CcSEcCtD
Neostigmine—Arrhythmia—Conjugated Estrogens—osteoporosis	0.00165	0.00234	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00165	0.00233	CcSEcCtD
Neostigmine—Syncope—Pamidronate—osteoporosis	0.00164	0.00233	CcSEcCtD
Neostigmine—Arthralgia—Risedronate—osteoporosis	0.00164	0.00232	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00163	0.00231	CcSEcCtD
Neostigmine—Pruritus—Etidronic acid—osteoporosis	0.00163	0.00231	CcSEcCtD
Neostigmine—Gastrointestinal pain—Estropipate—osteoporosis	0.00163	0.0023	CcSEcCtD
Neostigmine—Mental disorder—Conjugated Estrogens—osteoporosis	0.00162	0.0023	CcSEcCtD
Neostigmine—Loss of consciousness—Pamidronate—osteoporosis	0.00161	0.00228	CcSEcCtD
Neostigmine—Muscle spasms—Zoledronate—osteoporosis	0.00161	0.00228	CcSEcCtD
Neostigmine—Dry mouth—Risedronate—osteoporosis	0.0016	0.00227	CcSEcCtD
Neostigmine—Gastrointestinal pain—Alendronate—osteoporosis	0.0016	0.00227	CcSEcCtD
Neostigmine—Flatulence—Conjugated Estrogens—osteoporosis	0.00159	0.00225	CcSEcCtD
Neostigmine—Convulsion—Pamidronate—osteoporosis	0.00159	0.00225	CcSEcCtD
Neostigmine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00158	0.00224	CcSEcCtD
Neostigmine—Urticaria—Estropipate—osteoporosis	0.00158	0.00224	CcSEcCtD
Neostigmine—Gastrointestinal pain—Raloxifene—osteoporosis	0.00158	0.00223	CcSEcCtD
Neostigmine—Diarrhoea—Etidronic acid—osteoporosis	0.00157	0.00223	CcSEcCtD
Neostigmine—Abdominal pain—Estropipate—osteoporosis	0.00157	0.00223	CcSEcCtD
Neostigmine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00157	0.00222	CcSEcCtD
Neostigmine—Gastrointestinal pain—Ibandronate—osteoporosis	0.00156	0.00221	CcSEcCtD
Neostigmine—Arthralgia—Pamidronate—osteoporosis	0.00156	0.00221	CcSEcCtD
Neostigmine—Urticaria—Alendronate—osteoporosis	0.00156	0.00221	CcSEcCtD
Neostigmine—Abdominal pain—Alendronate—osteoporosis	0.00155	0.00219	CcSEcCtD
Neostigmine—Muscle spasms—Conjugated Estrogens—osteoporosis	0.00155	0.00219	CcSEcCtD
Neostigmine—Shock—Risedronate—osteoporosis	0.00155	0.00219	CcSEcCtD
Neostigmine—Nervous system disorder—Risedronate—osteoporosis	0.00154	0.00218	CcSEcCtD
Neostigmine—Agitation—Zoledronate—osteoporosis	0.00154	0.00218	CcSEcCtD
Neostigmine—Skin disorder—Risedronate—osteoporosis	0.00153	0.00216	CcSEcCtD
Neostigmine—Gastrointestinal pain—Calcitriol—osteoporosis	0.00153	0.00216	CcSEcCtD
Neostigmine—Abdominal pain—Raloxifene—osteoporosis	0.00152	0.00216	CcSEcCtD
Neostigmine—Urticaria—Ibandronate—osteoporosis	0.00152	0.00215	CcSEcCtD
Neostigmine—Abdominal pain—Ibandronate—osteoporosis	0.00151	0.00214	CcSEcCtD
Neostigmine—Syncope—Zoledronate—osteoporosis	0.0015	0.00213	CcSEcCtD
Neostigmine—Anaphylactic shock—Pamidronate—osteoporosis	0.00149	0.00212	CcSEcCtD
Neostigmine—Urticaria—Calcitriol—osteoporosis	0.00148	0.0021	CcSEcCtD
Neostigmine—Abdominal pain—Calcitriol—osteoporosis	0.00148	0.00209	CcSEcCtD
Neostigmine—Shock—Pamidronate—osteoporosis	0.00147	0.00208	CcSEcCtD
Neostigmine—Loss of consciousness—Zoledronate—osteoporosis	0.00147	0.00208	CcSEcCtD
Neostigmine—Hypersensitivity—Estropipate—osteoporosis	0.00147	0.00208	CcSEcCtD
Neostigmine—Nervous system disorder—Pamidronate—osteoporosis	0.00147	0.00208	CcSEcCtD
Neostigmine—Urinary tract disorder—Estradiol—osteoporosis	0.00146	0.00207	CcSEcCtD
Neostigmine—Vomiting—Etidronic acid—osteoporosis	0.00146	0.00207	CcSEcCtD
Neostigmine—Tachycardia—Pamidronate—osteoporosis	0.00146	0.00207	CcSEcCtD
Neostigmine—Connective tissue disorder—Estradiol—osteoporosis	0.00146	0.00206	CcSEcCtD
Neostigmine—Urethral disorder—Estradiol—osteoporosis	0.00145	0.00206	CcSEcCtD
Neostigmine—Rash—Etidronic acid—osteoporosis	0.00145	0.00205	CcSEcCtD
Neostigmine—Convulsion—Zoledronate—osteoporosis	0.00145	0.00205	CcSEcCtD
Neostigmine—Dermatitis—Etidronic acid—osteoporosis	0.00145	0.00205	CcSEcCtD
Neostigmine—Hyperhidrosis—Pamidronate—osteoporosis	0.00144	0.00205	CcSEcCtD
Neostigmine—Syncope—Conjugated Estrogens—osteoporosis	0.00144	0.00205	CcSEcCtD
Neostigmine—Hypersensitivity—Alendronate—osteoporosis	0.00144	0.00205	CcSEcCtD
Neostigmine—Headache—Etidronic acid—osteoporosis	0.00144	0.00204	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00143	0.00203	CcSEcCtD
Neostigmine—Asthenia—Estropipate—osteoporosis	0.00143	0.00202	CcSEcCtD
Neostigmine—Arthralgia—Zoledronate—osteoporosis	0.00142	0.00202	CcSEcCtD
Neostigmine—Insomnia—Risedronate—osteoporosis	0.00142	0.00201	CcSEcCtD
Neostigmine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00142	0.00201	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00141	0.002	CcSEcCtD
Neostigmine—Pruritus—Estropipate—osteoporosis	0.00141	0.00199	CcSEcCtD
Neostigmine—Asthenia—Alendronate—osteoporosis	0.00141	0.00199	CcSEcCtD
Neostigmine—Hypersensitivity—Ibandronate—osteoporosis	0.00141	0.00199	CcSEcCtD
Neostigmine—Dyspnoea—Risedronate—osteoporosis	0.0014	0.00199	CcSEcCtD
Neostigmine—Hypotension—Pamidronate—osteoporosis	0.0014	0.00198	CcSEcCtD
Neostigmine—Convulsion—Conjugated Estrogens—osteoporosis	0.0014	0.00198	CcSEcCtD
Neostigmine—Dry mouth—Zoledronate—osteoporosis	0.00139	0.00197	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00139	0.00197	CcSEcCtD
Neostigmine—Pruritus—Alendronate—osteoporosis	0.00139	0.00196	CcSEcCtD
Neostigmine—Hypersensitivity—Calcitriol—osteoporosis	0.00138	0.00195	CcSEcCtD
Neostigmine—Flushing—Estradiol—osteoporosis	0.00137	0.00195	CcSEcCtD
Neostigmine—Arthralgia—Conjugated Estrogens—osteoporosis	0.00137	0.00194	CcSEcCtD
Neostigmine—Asthenia—Ibandronate—osteoporosis	0.00137	0.00194	CcSEcCtD
Neostigmine—Nausea—Etidronic acid—osteoporosis	0.00137	0.00194	CcSEcCtD
Neostigmine—Anaphylactic shock—Zoledronate—osteoporosis	0.00137	0.00193	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00136	0.00193	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00136	0.00193	CcSEcCtD
Neostigmine—Diarrhoea—Estropipate—osteoporosis	0.00136	0.00193	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Risedronate—osteoporosis	0.00136	0.00192	CcSEcCtD
Neostigmine—Insomnia—Pamidronate—osteoporosis	0.00135	0.00192	CcSEcCtD
Neostigmine—Pruritus—Ibandronate—osteoporosis	0.00135	0.00191	CcSEcCtD
Neostigmine—Shock—Zoledronate—osteoporosis	0.00134	0.0019	CcSEcCtD
Neostigmine—Diarrhoea—Alendronate—osteoporosis	0.00134	0.0019	CcSEcCtD
Neostigmine—Asthenia—Calcitriol—osteoporosis	0.00134	0.0019	CcSEcCtD
Neostigmine—Nervous system disorder—Zoledronate—osteoporosis	0.00134	0.0019	CcSEcCtD
Neostigmine—Mediastinal disorder—Estradiol—osteoporosis	0.00133	0.00189	CcSEcCtD
Neostigmine—Dyspnoea—Pamidronate—osteoporosis	0.00133	0.00189	CcSEcCtD
Neostigmine—Tachycardia—Zoledronate—osteoporosis	0.00133	0.00189	CcSEcCtD
Neostigmine—Somnolence—Pamidronate—osteoporosis	0.00133	0.00188	CcSEcCtD
Neostigmine—Skin disorder—Zoledronate—osteoporosis	0.00133	0.00188	CcSEcCtD
Neostigmine—Pruritus—Calcitriol—osteoporosis	0.00132	0.00187	CcSEcCtD
Neostigmine—Hyperhidrosis—Zoledronate—osteoporosis	0.00132	0.00187	CcSEcCtD
Neostigmine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00132	0.00187	CcSEcCtD
Neostigmine—Diarrhoea—Raloxifene—osteoporosis	0.00132	0.00187	CcSEcCtD
Neostigmine—ACHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—osteoporosis	0.00132	0.0337	CbGpPWpGaD
Neostigmine—Dizziness—Estropipate—osteoporosis	0.00132	0.00186	CcSEcCtD
Neostigmine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00131	0.00186	CcSEcCtD
Neostigmine—Diarrhoea—Ibandronate—osteoporosis	0.00131	0.00185	CcSEcCtD
Neostigmine—Mental disorder—Estradiol—osteoporosis	0.0013	0.00184	CcSEcCtD
Neostigmine—Dizziness—Alendronate—osteoporosis	0.0013	0.00184	CcSEcCtD
Neostigmine—Shock—Conjugated Estrogens—osteoporosis	0.00129	0.00183	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00129	0.00183	CcSEcCtD
Neostigmine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00129	0.00183	CcSEcCtD
Neostigmine—Gastrointestinal pain—Risedronate—osteoporosis	0.00129	0.00182	CcSEcCtD
Neostigmine—Tachycardia—Conjugated Estrogens—osteoporosis	0.00128	0.00182	CcSEcCtD
Neostigmine—Urticaria—Ethinyl Estradiol—osteoporosis	0.00128	0.00181	CcSEcCtD
Neostigmine—Diarrhoea—Calcitriol—osteoporosis	0.00128	0.00181	CcSEcCtD
Neostigmine—Skin disorder—Conjugated Estrogens—osteoporosis	0.00128	0.00181	CcSEcCtD
Neostigmine—Hypotension—Zoledronate—osteoporosis	0.00128	0.00181	CcSEcCtD
Neostigmine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00127	0.00181	CcSEcCtD
Neostigmine—Dizziness—Raloxifene—osteoporosis	0.00127	0.00181	CcSEcCtD
Neostigmine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00127	0.0018	CcSEcCtD
Neostigmine—Flatulence—Estradiol—osteoporosis	0.00127	0.0018	CcSEcCtD
Neostigmine—Vomiting—Estropipate—osteoporosis	0.00127	0.00179	CcSEcCtD
Neostigmine—Dizziness—Ibandronate—osteoporosis	0.00126	0.00179	CcSEcCtD
Neostigmine—Rash—Estropipate—osteoporosis	0.00125	0.00178	CcSEcCtD
Neostigmine—Dermatitis—Estropipate—osteoporosis	0.00125	0.00178	CcSEcCtD
Neostigmine—Urticaria—Risedronate—osteoporosis	0.00125	0.00177	CcSEcCtD
Neostigmine—Headache—Estropipate—osteoporosis	0.00125	0.00177	CcSEcCtD
Neostigmine—Vomiting—Alendronate—osteoporosis	0.00125	0.00177	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00124	0.00176	CcSEcCtD
Neostigmine—Abdominal pain—Risedronate—osteoporosis	0.00124	0.00176	CcSEcCtD
Neostigmine—Muscle spasms—Estradiol—osteoporosis	0.00124	0.00176	CcSEcCtD
Neostigmine—Rash—Alendronate—osteoporosis	0.00124	0.00175	CcSEcCtD
Neostigmine—Insomnia—Zoledronate—osteoporosis	0.00123	0.00175	CcSEcCtD
Neostigmine—Dermatitis—Alendronate—osteoporosis	0.00123	0.00175	CcSEcCtD
Neostigmine—Hypotension—Conjugated Estrogens—osteoporosis	0.00123	0.00174	CcSEcCtD
Neostigmine—Headache—Alendronate—osteoporosis	0.00123	0.00174	CcSEcCtD
Neostigmine—Vomiting—Raloxifene—osteoporosis	0.00123	0.00174	CcSEcCtD
Neostigmine—Gastrointestinal pain—Pamidronate—osteoporosis	0.00122	0.00173	CcSEcCtD
Neostigmine—Dyspnoea—Zoledronate—osteoporosis	0.00122	0.00172	CcSEcCtD
Neostigmine—Rash—Raloxifene—osteoporosis	0.00122	0.00172	CcSEcCtD
Neostigmine—Dermatitis—Raloxifene—osteoporosis	0.00121	0.00172	CcSEcCtD
Neostigmine—Somnolence—Zoledronate—osteoporosis	0.00121	0.00172	CcSEcCtD
Neostigmine—Vomiting—Ibandronate—osteoporosis	0.00121	0.00172	CcSEcCtD
Neostigmine—Headache—Raloxifene—osteoporosis	0.00121	0.00171	CcSEcCtD
Neostigmine—Rash—Ibandronate—osteoporosis	0.0012	0.0017	CcSEcCtD
Neostigmine—ACHE—Glycerophospholipid biosynthesis—MGLL—osteoporosis	0.0012	0.0308	CbGpPWpGaD
Neostigmine—Dermatitis—Ibandronate—osteoporosis	0.0012	0.0017	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.0012	0.0017	CcSEcCtD
Neostigmine—Headache—Ibandronate—osteoporosis	0.0012	0.00169	CcSEcCtD
Neostigmine—Insomnia—Conjugated Estrogens—osteoporosis	0.00119	0.00168	CcSEcCtD
Neostigmine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00119	0.00168	CcSEcCtD
Neostigmine—Vomiting—Calcitriol—osteoporosis	0.00119	0.00168	CcSEcCtD
Neostigmine—Agitation—Estradiol—osteoporosis	0.00118	0.00168	CcSEcCtD
Neostigmine—Nausea—Estropipate—osteoporosis	0.00118	0.00167	CcSEcCtD
Neostigmine—Abdominal pain—Pamidronate—osteoporosis	0.00118	0.00167	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00118	0.00167	CcSEcCtD
Neostigmine—Rash—Calcitriol—osteoporosis	0.00118	0.00167	CcSEcCtD
Neostigmine—Dermatitis—Calcitriol—osteoporosis	0.00118	0.00167	CcSEcCtD
Neostigmine—BCHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—osteoporosis	0.00117	0.0301	CbGpPWpGaD
Neostigmine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00117	0.00166	CcSEcCtD
Neostigmine—Headache—Calcitriol—osteoporosis	0.00117	0.00166	CcSEcCtD
Neostigmine—Somnolence—Conjugated Estrogens—osteoporosis	0.00117	0.00166	CcSEcCtD
Neostigmine—Nausea—Alendronate—osteoporosis	0.00116	0.00165	CcSEcCtD
Neostigmine—Hypersensitivity—Risedronate—osteoporosis	0.00116	0.00164	CcSEcCtD
Neostigmine—Asthenia—Ethinyl Estradiol—osteoporosis	0.00116	0.00164	CcSEcCtD
Neostigmine—Syncope—Estradiol—osteoporosis	0.00116	0.00164	CcSEcCtD
Neostigmine—Nausea—Raloxifene—osteoporosis	0.00114	0.00162	CcSEcCtD
Neostigmine—Pruritus—Ethinyl Estradiol—osteoporosis	0.00114	0.00162	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00113	0.00161	CcSEcCtD
Neostigmine—Nausea—Ibandronate—osteoporosis	0.00113	0.00161	CcSEcCtD
Neostigmine—Loss of consciousness—Estradiol—osteoporosis	0.00113	0.00161	CcSEcCtD
Neostigmine—Asthenia—Risedronate—osteoporosis	0.00113	0.0016	CcSEcCtD
Neostigmine—Gastrointestinal pain—Zoledronate—osteoporosis	0.00112	0.00158	CcSEcCtD
Neostigmine—Pruritus—Risedronate—osteoporosis	0.00111	0.00158	CcSEcCtD
Neostigmine—Nausea—Calcitriol—osteoporosis	0.00111	0.00157	CcSEcCtD
Neostigmine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.0011	0.00156	CcSEcCtD
Neostigmine—Hypersensitivity—Pamidronate—osteoporosis	0.0011	0.00156	CcSEcCtD
Neostigmine—Arthralgia—Estradiol—osteoporosis	0.0011	0.00155	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00109	0.00154	CcSEcCtD
Neostigmine—ACHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—osteoporosis	0.00109	0.0278	CbGpPWpGaD
Neostigmine—Urticaria—Zoledronate—osteoporosis	0.00108	0.00154	CcSEcCtD
Neostigmine—Abdominal pain—Zoledronate—osteoporosis	0.00108	0.00153	CcSEcCtD
Neostigmine—Diarrhoea—Risedronate—osteoporosis	0.00108	0.00152	CcSEcCtD
Neostigmine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00108	0.00152	CcSEcCtD
Neostigmine—Dry mouth—Estradiol—osteoporosis	0.00107	0.00152	CcSEcCtD
Neostigmine—BCHE—Glycerophospholipid biosynthesis—MGLL—osteoporosis	0.00107	0.0275	CbGpPWpGaD
Neostigmine—Asthenia—Pamidronate—osteoporosis	0.00107	0.00152	CcSEcCtD
Neostigmine—Dizziness—Ethinyl Estradiol—osteoporosis	0.00107	0.00151	CcSEcCtD
Neostigmine—Pruritus—Pamidronate—osteoporosis	0.00106	0.0015	CcSEcCtD
Neostigmine—Anaphylactic shock—Estradiol—osteoporosis	0.00105	0.00149	CcSEcCtD
Neostigmine—Urticaria—Conjugated Estrogens—osteoporosis	0.00104	0.00148	CcSEcCtD
Neostigmine—Dizziness—Risedronate—osteoporosis	0.00104	0.00147	CcSEcCtD
Neostigmine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00104	0.00147	CcSEcCtD
Neostigmine—Shock—Estradiol—osteoporosis	0.00104	0.00147	CcSEcCtD
Neostigmine—Nervous system disorder—Estradiol—osteoporosis	0.00103	0.00146	CcSEcCtD
Neostigmine—Tachycardia—Estradiol—osteoporosis	0.00103	0.00145	CcSEcCtD
Neostigmine—Vomiting—Ethinyl Estradiol—osteoporosis	0.00103	0.00145	CcSEcCtD
Neostigmine—Diarrhoea—Pamidronate—osteoporosis	0.00102	0.00145	CcSEcCtD
Neostigmine—Skin disorder—Estradiol—osteoporosis	0.00102	0.00145	CcSEcCtD
Neostigmine—Hyperhidrosis—Estradiol—osteoporosis	0.00102	0.00144	CcSEcCtD
Neostigmine—Rash—Ethinyl Estradiol—osteoporosis	0.00102	0.00144	CcSEcCtD
Neostigmine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00102	0.00144	CcSEcCtD
Neostigmine—Headache—Ethinyl Estradiol—osteoporosis	0.00101	0.00143	CcSEcCtD
Neostigmine—Hypersensitivity—Zoledronate—osteoporosis	0.00101	0.00143	CcSEcCtD
Neostigmine—Vomiting—Risedronate—osteoporosis	0.001	0.00142	CcSEcCtD
Neostigmine—Rash—Risedronate—osteoporosis	0.000991	0.0014	CcSEcCtD
Neostigmine—Dermatitis—Risedronate—osteoporosis	0.00099	0.0014	CcSEcCtD
Neostigmine—Dizziness—Pamidronate—osteoporosis	0.000988	0.0014	CcSEcCtD
Neostigmine—Headache—Risedronate—osteoporosis	0.000985	0.0014	CcSEcCtD
Neostigmine—Asthenia—Zoledronate—osteoporosis	0.00098	0.00139	CcSEcCtD
Neostigmine—BCHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—osteoporosis	0.00097	0.0248	CbGpPWpGaD
Neostigmine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000969	0.00137	CcSEcCtD
Neostigmine—Pruritus—Zoledronate—osteoporosis	0.000966	0.00137	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000959	0.00136	CcSEcCtD
Neostigmine—Nausea—Ethinyl Estradiol—osteoporosis	0.000958	0.00136	CcSEcCtD
Neostigmine—Insomnia—Estradiol—osteoporosis	0.000952	0.00135	CcSEcCtD
Neostigmine—Vomiting—Pamidronate—osteoporosis	0.00095	0.00135	CcSEcCtD
Neostigmine—Asthenia—Conjugated Estrogens—osteoporosis	0.000943	0.00134	CcSEcCtD
Neostigmine—Rash—Pamidronate—osteoporosis	0.000942	0.00134	CcSEcCtD
Neostigmine—Dermatitis—Pamidronate—osteoporosis	0.000942	0.00133	CcSEcCtD
Neostigmine—Dyspnoea—Estradiol—osteoporosis	0.000938	0.00133	CcSEcCtD
Neostigmine—ACHE—Peptide hormone metabolism—REN—osteoporosis	0.000937	0.024	CbGpPWpGaD
Neostigmine—Headache—Pamidronate—osteoporosis	0.000936	0.00133	CcSEcCtD
Neostigmine—Somnolence—Estradiol—osteoporosis	0.000935	0.00133	CcSEcCtD
Neostigmine—Diarrhoea—Zoledronate—osteoporosis	0.000934	0.00132	CcSEcCtD
Neostigmine—Nausea—Risedronate—osteoporosis	0.000934	0.00132	CcSEcCtD
Neostigmine—Pruritus—Conjugated Estrogens—osteoporosis	0.00093	0.00132	CcSEcCtD
Neostigmine—ABCB1—HIF-1-alpha transcription factor network—PKM—osteoporosis	0.000917	0.0235	CbGpPWpGaD
Neostigmine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000908	0.00129	CcSEcCtD
Neostigmine—Dizziness—Zoledronate—osteoporosis	0.000903	0.00128	CcSEcCtD
Neostigmine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.0009	0.00127	CcSEcCtD
Neostigmine—Nausea—Pamidronate—osteoporosis	0.000888	0.00126	CcSEcCtD
Neostigmine—Dizziness—Conjugated Estrogens—osteoporosis	0.000869	0.00123	CcSEcCtD
Neostigmine—Vomiting—Zoledronate—osteoporosis	0.000868	0.00123	CcSEcCtD
Neostigmine—Rash—Zoledronate—osteoporosis	0.000861	0.00122	CcSEcCtD
Neostigmine—Gastrointestinal pain—Estradiol—osteoporosis	0.00086	0.00122	CcSEcCtD
Neostigmine—Dermatitis—Zoledronate—osteoporosis	0.00086	0.00122	CcSEcCtD
Neostigmine—Headache—Zoledronate—osteoporosis	0.000855	0.00121	CcSEcCtD
Neostigmine—ACHE—Phospholipid metabolism—MGLL—osteoporosis	0.000839	0.0215	CbGpPWpGaD
Neostigmine—Vomiting—Conjugated Estrogens—osteoporosis	0.000836	0.00118	CcSEcCtD
Neostigmine—Urticaria—Estradiol—osteoporosis	0.000836	0.00118	CcSEcCtD
Neostigmine—BCHE—Peptide hormone metabolism—REN—osteoporosis	0.000836	0.0214	CbGpPWpGaD
Neostigmine—Abdominal pain—Estradiol—osteoporosis	0.000832	0.00118	CcSEcCtD
Neostigmine—Rash—Conjugated Estrogens—osteoporosis	0.000829	0.00117	CcSEcCtD
Neostigmine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000828	0.00117	CcSEcCtD
Neostigmine—Headache—Conjugated Estrogens—osteoporosis	0.000824	0.00117	CcSEcCtD
Neostigmine—Nausea—Zoledronate—osteoporosis	0.000811	0.00115	CcSEcCtD
Neostigmine—Nausea—Conjugated Estrogens—osteoporosis	0.000781	0.00111	CcSEcCtD
Neostigmine—Hypersensitivity—Estradiol—osteoporosis	0.000775	0.0011	CcSEcCtD
Neostigmine—Asthenia—Estradiol—osteoporosis	0.000755	0.00107	CcSEcCtD
Neostigmine—BCHE—Phospholipid metabolism—MGLL—osteoporosis	0.000748	0.0192	CbGpPWpGaD
Neostigmine—Pruritus—Estradiol—osteoporosis	0.000744	0.00105	CcSEcCtD
Neostigmine—Diarrhoea—Estradiol—osteoporosis	0.00072	0.00102	CcSEcCtD
Neostigmine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000716	0.0183	CbGpPWpGaD
Neostigmine—Dizziness—Estradiol—osteoporosis	0.000696	0.000986	CcSEcCtD
Neostigmine—Vomiting—Estradiol—osteoporosis	0.000669	0.000948	CcSEcCtD
Neostigmine—Rash—Estradiol—osteoporosis	0.000663	0.00094	CcSEcCtD
Neostigmine—Dermatitis—Estradiol—osteoporosis	0.000663	0.000939	CcSEcCtD
Neostigmine—Headache—Estradiol—osteoporosis	0.000659	0.000934	CcSEcCtD
Neostigmine—ABCB1—Allograft Rejection—TUBA1B—osteoporosis	0.00064	0.0164	CbGpPWpGaD
Neostigmine—Nausea—Estradiol—osteoporosis	0.000625	0.000885	CcSEcCtD
Neostigmine—ACHE—Peptide hormone metabolism—ACE—osteoporosis	0.000585	0.015	CbGpPWpGaD
Neostigmine—BCHE—Peptide hormone metabolism—ACE—osteoporosis	0.000522	0.0134	CbGpPWpGaD
Neostigmine—ACHE—Monoamine Transport—IL1B—osteoporosis	0.000506	0.013	CbGpPWpGaD
Neostigmine—ACHE—ATF-2 transcription factor network—ESR1—osteoporosis	0.000464	0.0119	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.00042	0.0108	CbGpPWpGaD
Neostigmine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000411	0.0105	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000376	0.00963	CbGpPWpGaD
Neostigmine—ACHE—Monoamine Transport—TNF—osteoporosis	0.000367	0.0094	CbGpPWpGaD
Neostigmine—ACHE—Peptide hormone metabolism—LEP—osteoporosis	0.000363	0.0093	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000356	0.00912	CbGpPWpGaD
Neostigmine—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000346	0.00886	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000335	0.00859	CbGpPWpGaD
Neostigmine—BCHE—Peptide hormone metabolism—LEP—osteoporosis	0.000324	0.0083	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000318	0.00814	CbGpPWpGaD
Neostigmine—ACHE—Peptide hormone metabolism—POMC—osteoporosis	0.000312	0.00799	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—CCT2—osteoporosis	0.000308	0.00788	CbGpPWpGaD
Neostigmine—ACHE—Peptide hormone metabolism—IGF1—osteoporosis	0.0003	0.00768	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000299	0.00766	CbGpPWpGaD
Neostigmine—BCHE—Peptide hormone metabolism—POMC—osteoporosis	0.000278	0.00713	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000277	0.0071	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—CCT2—osteoporosis	0.000275	0.00703	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.00027	0.00692	CbGpPWpGaD
Neostigmine—BCHE—Peptide hormone metabolism—IGF1—osteoporosis	0.000268	0.00685	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—TUBA1B—osteoporosis	0.000262	0.0067	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000247	0.00633	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000241	0.00617	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—TUBA1B—osteoporosis	0.000234	0.00598	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000216	0.00553	CbGpPWpGaD
Neostigmine—ACHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000214	0.00548	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—RPL24—osteoporosis	0.000209	0.00536	CbGpPWpGaD
Neostigmine—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000194	0.00496	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000193	0.00493	CbGpPWpGaD
Neostigmine—BCHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000191	0.00489	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—RPL24—osteoporosis	0.000187	0.00478	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—TLN1—osteoporosis	0.000184	0.00471	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000184	0.0047	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000183	0.00468	CbGpPWpGaD
Neostigmine—ACHE—ATF-2 transcription factor network—IL6—osteoporosis	0.000182	0.00465	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000181	0.00465	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—REN—osteoporosis	0.000177	0.00453	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—FDPS—osteoporosis	0.000167	0.00429	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—PKM—osteoporosis	0.000167	0.00429	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—TLN1—osteoporosis	0.000164	0.0042	CbGpPWpGaD
Neostigmine—ACHE—Neuronal System—ADCY5—osteoporosis	0.000164	0.0042	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000164	0.00419	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—GPD2—osteoporosis	0.000159	0.00406	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—PGLS—osteoporosis	0.000159	0.00406	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—REN—osteoporosis	0.000158	0.00404	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000157	0.00402	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—PKM—osteoporosis	0.000149	0.00382	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—FDPS—osteoporosis	0.000149	0.00382	CbGpPWpGaD
Neostigmine—BCHE—Neuronal System—ADCY5—osteoporosis	0.000146	0.00374	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—ATIC—osteoporosis	0.000145	0.00372	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—PNP—osteoporosis	0.000145	0.00372	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—PGLS—osteoporosis	0.000142	0.00363	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—GPD2—osteoporosis	0.000142	0.00363	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.00013	0.00333	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—PNP—osteoporosis	0.000129	0.00332	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—ATIC—osteoporosis	0.000129	0.00332	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—OXCT1—osteoporosis	0.000123	0.00316	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—CA2—osteoporosis	0.000123	0.00316	CbGpPWpGaD
Neostigmine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	0.000122	0.00312	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—MGLL—osteoporosis	0.00012	0.00308	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000113	0.0029	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—ACE—osteoporosis	0.00011	0.00283	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—OXCT1—osteoporosis	0.00011	0.00282	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—CA2—osteoporosis	0.00011	0.00282	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—MGLL—osteoporosis	0.000107	0.00275	CbGpPWpGaD
Neostigmine—ABCB1—Allograft Rejection—IL1B—osteoporosis	0.000107	0.00274	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—IDH2—osteoporosis	0.000102	0.00262	CbGpPWpGaD
Neostigmine—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000102	0.00262	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000101	0.00259	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—ACE—osteoporosis	9.85e-05	0.00252	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—CYP27A1—osteoporosis	9.61e-05	0.00246	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	9.44e-05	0.00242	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	9.41e-05	0.00241	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—ACP5—osteoporosis	9.35e-05	0.0024	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.23e-05	0.00236	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—IDH2—osteoporosis	9.12e-05	0.00234	CbGpPWpGaD
Neostigmine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	8.79e-05	0.00225	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—TPI1—osteoporosis	8.7e-05	0.00223	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—CYP27A1—osteoporosis	8.58e-05	0.0022	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—ACP5—osteoporosis	8.34e-05	0.00214	CbGpPWpGaD
Neostigmine—ABCB1—Allograft Rejection—TGFB1—osteoporosis	8.3e-05	0.00213	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	8.24e-05	0.00211	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—P4HB—osteoporosis	8.18e-05	0.00209	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—GAPDH—osteoporosis	8.02e-05	0.00205	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	7.9e-05	0.00202	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—RAP1A—osteoporosis	7.82e-05	0.002	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—TPI1—osteoporosis	7.76e-05	0.00199	CbGpPWpGaD
Neostigmine—ABCB1—Allograft Rejection—TNF—osteoporosis	7.75e-05	0.00199	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—P4HB—osteoporosis	7.29e-05	0.00187	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—PKM—osteoporosis	7.29e-05	0.00187	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—FDPS—osteoporosis	7.29e-05	0.00187	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—GAPDH—osteoporosis	7.16e-05	0.00183	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—RAP1A—osteoporosis	6.97e-05	0.00179	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—PGLS—osteoporosis	6.91e-05	0.00177	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—GPD2—osteoporosis	6.91e-05	0.00177	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—LEP—osteoporosis	6.86e-05	0.00176	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	6.83e-05	0.00175	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.82e-05	0.00175	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—ENO1—osteoporosis	6.32e-05	0.00162	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—PNP—osteoporosis	6.32e-05	0.00162	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—ATIC—osteoporosis	6.32e-05	0.00162	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—PSMA5—osteoporosis	6.23e-05	0.00159	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—PSMA2—osteoporosis	6.23e-05	0.00159	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—LEP—osteoporosis	6.12e-05	0.00157	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.08e-05	0.00156	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—POMC—osteoporosis	5.89e-05	0.00151	CbGpPWpGaD
Neostigmine—ACHE—Metabolism of proteins—IGF1—osteoporosis	5.67e-05	0.00145	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—ENO1—osteoporosis	5.64e-05	0.00144	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—PSMA2—osteoporosis	5.55e-05	0.00142	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—PSMA5—osteoporosis	5.55e-05	0.00142	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—CA2—osteoporosis	5.37e-05	0.00138	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—OXCT1—osteoporosis	5.37e-05	0.00138	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—POMC—osteoporosis	5.25e-05	0.00135	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—MGLL—osteoporosis	5.24e-05	0.00134	CbGpPWpGaD
Neostigmine—BCHE—Metabolism of proteins—IGF1—osteoporosis	5.05e-05	0.00129	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—CYP19A1—osteoporosis	5.05e-05	0.00129	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—CYP19A1—osteoporosis	4.51e-05	0.00115	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—IDH2—osteoporosis	4.45e-05	0.00114	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—CYP27A1—osteoporosis	4.19e-05	0.00107	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—ADCY5—osteoporosis	4.13e-05	0.00106	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—GPX1—osteoporosis	4.11e-05	0.00105	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	4.11e-05	0.00105	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	4.1e-05	0.00105	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—ACP5—osteoporosis	4.07e-05	0.00104	CbGpPWpGaD
Neostigmine—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.84e-05	0.000982	CbGpPWpGaD
Neostigmine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.83e-05	0.00098	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—MTHFR—osteoporosis	3.8e-05	0.000972	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—TPI1—osteoporosis	3.78e-05	0.000969	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—ADCY5—osteoporosis	3.68e-05	0.000943	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—GPX1—osteoporosis	3.67e-05	0.000939	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—P4HB—osteoporosis	3.56e-05	0.000911	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—GAPDH—osteoporosis	3.49e-05	0.000894	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—RAP1A—osteoporosis	3.4e-05	0.000871	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—MTHFR—osteoporosis	3.39e-05	0.000867	CbGpPWpGaD
Neostigmine—ACHE—Metabolism—POMC—osteoporosis	3.04e-05	0.000777	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—ENO1—osteoporosis	2.75e-05	0.000704	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—PSMA5—osteoporosis	2.71e-05	0.000694	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—PSMA2—osteoporosis	2.71e-05	0.000694	CbGpPWpGaD
Neostigmine—BCHE—Metabolism—POMC—osteoporosis	2.71e-05	0.000693	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—CYP19A1—osteoporosis	2.2e-05	0.000563	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—ADCY5—osteoporosis	1.8e-05	0.00046	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—GPX1—osteoporosis	1.79e-05	0.000458	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—MTHFR—osteoporosis	1.65e-05	0.000423	CbGpPWpGaD
Neostigmine—ABCB1—Metabolism—POMC—osteoporosis	1.32e-05	0.000338	CbGpPWpGaD
